This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

MR Colonography With Fecal Tagging. Barium vs. BariumFerumoxsil

This study has been completed.
University Hospital, Gentofte, Copenhagen
Information provided by:
Herlev Hospital Identifier:
First received: June 1, 2006
Last updated: September 19, 2007
Last verified: September 2007
The purpose of this study is to determine whether Barium or BariumFerumoxsil is better for fecal tagging in MR colonography. Patients referred to colonoscopy are offered MR colonography before colonoscopy. Two days before colonography, patients ingest either a contrast agent A (200 ml Barium sulphate solution 1g/ml)) four times a day or a 200 ml contrast agent B (Barium sulfate(25%) and Ferumoxil(75%)) four times a day, which will render fecal masses "invisible" on the following MR colonography. The patients are randomised to either contrast agent A or B. The examinations are evaluated by two independent blinded readers, who will rate the tagging quality of the contrast agents. The quality of tagging will be rated by a Visual Analog Scale (VAS) and Relative contrast (ReCon = Iwall - Ilumen/ Iwall + Ilumen).

Condition Intervention Phase
Colorectal Cancer Polyps Procedure: MR colonography with fecal tagging Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Diagnostic
Official Title: MR Colonography With Fecal Tagging. Barium vs. BariumFerumoxsil

Resource links provided by NLM:

Further study details as provided by Herlev Hospital:

Primary Outcome Measures:
  • Quality of fecal tagging agent
  • Sensitivity of VAS score vs. ReCon score

Estimated Enrollment: 20
Study Start Date: December 2005
Study Completion Date: May 2006

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Suspicion of colorectal polyps or cancer
  • Referred for colonoscopy

Exclusion Criteria:

  • Suspicion of IBD
  • Pacemaker
  • Metal in the body
  • Claustrophobia
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00332943

Department of Radiology Copenhagen University Hospital Herlev
Copenhagen, Denmark
Sponsors and Collaborators
Herlev Hospital
University Hospital, Gentofte, Copenhagen
Principal Investigator: Michael P Achiam, MD Department of Radiology Copenhagen University Hospital Herlev
  More Information Identifier: NCT00332943     History of Changes
Other Study ID Numbers: KA-20060039 MA
Study First Received: June 1, 2006
Last Updated: September 19, 2007

Keywords provided by Herlev Hospital:
colorectal polyps
colorectal cancer
Virtual colonoscopy
Fecal tagging
MR colonography

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases processed this record on August 18, 2017